Cobra Biomanufacturing Plc. (AIM: CBF), today announces an agreement with Debiopharm S.A., a Swiss drug development company, for the manufacture of the biopharmaceutical protein huTNFa Kinoid. The agreement includes process development and supply of material for clinical trials. The new agreement replaces a prior manufacturing deal with Neovacs SA, who has licensed the programme to Debiopharm.
